Compare NKE & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NKE | BDX |
|---|---|---|
| Founded | 1964 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.9B | 54.6B |
| IPO Year | 1999 | 1999 |
| Metric | NKE | BDX |
|---|---|---|
| Price | $37.69 | $215.35 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 44 | 16 |
| Target Price | $36.46 | ★ $226.14 |
| AVG Volume (30 Days) | ★ 18.7M | 1.8M |
| Earning Date | 12-17-2026 | 11-05-2026 |
| Dividend Yield | ★ 4.28% | 1.98% |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.48 | ★ 1.59 |
| Revenue | ★ $46,398,000,000.00 | $21,840,000,000.00 |
| Revenue This Year | N/A | $1.74 |
| Revenue Next Year | $0.72 | $4.24 |
| P/E Ratio | ★ $79.78 | $134.67 |
| Revenue Growth | 0.19 | ★ 8.24 |
| 52 Week Low | $32.76 | $140.11 |
| 52 Week High | $69.14 | $216.74 |
| Indicator | NKE | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 48.68 | 73.59 |
| Support Level | $36.84 | $175.60 |
| Resistance Level | $41.22 | N/A |
| Average True Range (ATR) | 1.08 | 4.59 |
| MACD | -0.06 | 1.13 |
| Stochastic Oscillator | 20.62 | 93.02 |
Nike is the largest athletic footwear and apparel brand in the world. Footwear generates about two-thirds of its sales. Key performance footwear categories include basketball, running, and football (soccer). Its brands include Nike, Jordan (premium athletic footwear and clothing), NikeSkims (women's athleisure), and Converse (casual footwear). Nike sells products worldwide through company-owned stores, franchised stores (including about 5,500 in China), and third-party retailers. The firm also operates e-commerce platforms in more than 40 countries. Nearly all its production is outsourced to contract manufacturers in more than 30 countries. Nike was founded in 1964 and is based in Beaverton, Oregon.
Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.